Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2014

View Archived Issues

Clearance of hepatic sphingomyelin in patients with Niemann-Pick disease type B treated with rhASM

HMOX1 genetic variations associated with severe malarial anemia

Presidio enters into two agreements for HCV NS5A inhibitor PPI-668

Boehringer Ingelheim plans phase II trial of BI-409306 in patients with schizophrenia

Novavax begins phase I trial of RSV F Vaccine in pediatric subjects

Janssen to begin phase I study of JNJ-49122944

OncoSec Medical receives grant to identify biomarkers for response to IL-12 gene therapy

Promising topline data from phase II study of tivantinib in metastatic prostate cancer

GE Healthcare and Takeda form liver fibrosis imaging collaboration

Ono Pharmaceutical reviews milestones of second quarter of fiscal 2014

Bionomics plans further clinical development of BNC-210

Results presented for a number of biomarkers of inflammatory bowel disease

Phase I results demonstrate the potential of LUM-002 in treatment of NASH

EnGeneIC initiates phase I trial of miR-16 in MPM

PBI-4050 cleared to commence trials in patients with diabetic kidney disease

AVEO Oncology enters into agreement with Ophthotech for tivozanib

Merck & Co. patents detail novel orexin antagonists

Threshold Pharmaceuticals receives FDA fast track designation for TH-302

Kissei Pharmaceutical reports development of D2 receptor agonists

iBio licenses technology to Caliber for production of Ebola virus antibodies

Japan researchers prepare and test novel anti-HB-EGF MAbs

Daiichi Sankyo patents new phosphate transporter inhibitors

Kaketsuken launches Byclot combination for intravenous injection in Japan

Czech organizations report tamoxifen derivatives

Brodalumab superior to ustekinumab in phase III trial in moderate to severe plaque psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...